Quantum Genomics : Failure of the FRESH phase 3
>Statistically insignificant efficacy - Quantum Genomics announced this morning the failure of its FRESH phase 3 study evaluating firibastat in patients with refractory arterial hypertension. Without communicating the details of the results, the biotech announced that the firibastat efficacy data are statistically insignificant vs placebo (as a reminder, the study aimed to demonstrate the reduction in systolic blood pressure after 84 days of firibastat in patients wit...Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.